Rodman & Renshaw Begins Coverage on Telomir Pharmaceuticals (NASDAQ:TELO)

Equities research analysts at Rodman & Renshaw started coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Rodman & Renshaw’s price objective points to a potential upside of 258.85% from the company’s previous close.

Telomir Pharmaceuticals Stock Performance

Telomir Pharmaceuticals stock opened at $4.18 on Friday. The firm has a 50 day moving average price of $4.56 and a 200 day moving average price of $4.85. The company has a market cap of $124.41 million and a price-to-earnings ratio of -7.21. Telomir Pharmaceuticals has a 1 year low of $3.11 and a 1 year high of $9.54.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). Sell-side analysts predict that Telomir Pharmaceuticals will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TELO. Barclays PLC lifted its stake in shares of Telomir Pharmaceuticals by 325.1% in the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after acquiring an additional 5,367 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Telomir Pharmaceuticals by 259.8% in the third quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock valued at $1,533,000 after buying an additional 172,382 shares during the period. State Street Corp raised its position in Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Telomir Pharmaceuticals by 458.3% during the 4th quarter. Wells Fargo & Company MN now owns 10,044 shares of the company’s stock valued at $41,000 after purchasing an additional 8,245 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Telomir Pharmaceuticals by 1,096.4% during the fourth quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company’s stock valued at $171,000 after purchasing an additional 37,980 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.